3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Lymphoid
3
Head & Neck
2
Gastrointestinal
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Solid Tumor
1
Interventions
pembrolizumab
26
Pemetrexed
26
Cisplatin
25
Nivolumab
22
Carboplatin
16
Paclitaxel
14
Gemcitabine
12
Ipilimumab
11
tislelizumab
8
durvalumab
8
Ramucirumab
8
Docetaxel
8
talazoparib
7
Fluorouracil
7
Radiotherapy
6
Capecitabine
6
tremelimumab
5
cobimetinib
5
atezolizumab
5
adavosertib
5
Radiosurgery
5
Cyclophosphamide
5
Bevacizumab
5
olaparib
4
avelumab
4
Temozolomide
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
magrolimab
×
Other solid neoplasm
×
Clear all
NCT04827576
2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2
Terminated
106 enrolled
22 charts